UT-34 is a potent, orally bioavailable pan-androgen receptor antagonist and degrader effective against wild-type and mutant (F876L, W741L) AR. It demonstrates anti-tumor activity in prostate cancer models, making it a valuable research tool for investigating AR signaling and therapeutic resistance in both in vitro and in vivo studies.